Participation in "Kusuri Visionary Meeting 2024" Aiming for Dialogue and Co-creation Among Diverse Stakeholders
Aiming for Dialogue and Co-creation Among Diverse Stakeholders
November 27, 2024
Japan Pharmaceutical Manufacturers Association (JPMA) announces its participation in the "Kusuri Visionary Meeting 2024" (
hereafter referred to as "the Meeting"), an initiative involving seven organizations and theJPMA. hereafter referred to as "the Meeting"), an initiative involving seven organizations and groups* representing patient organizations, government The Meeting, proposed by the Japan Federation of Medical Organizations of Japan, will be held in Tokyo, Japan.
The Meeting, proposed by Japan Federation of Cancer Patient Groups, aims to collaborate with a wide range of stakeholders to solve issues related to healthcare and medicines, promote patient involvement
Under the theme "Aiming to Improve Access to Drugs," the
Meeting was held on November 1, 2011.
Participants exchanged opinions on two topics: 1) Patient Involvement in Pharmaceutical Research and
At the conclusion, it was confirmed that this At the conclusion, it was confirmed that this Meeting should not be a one-time event, and that each stakeholder needs to play their role and cooperate.
Finally, as a message to society, allparticipants agreed to the following:
[Joint Message] [Joint Message] [Joint Message] [Joint Message[Joint Message] For the Japanese people to lead better lives
For the Japanese people to lead better lives, it is important to create a place for open dialogue among various stakeholders about issues related to For the Japanese people to lead better lives, it is important to create a place for open dialogue among various stakeholders about issues related to medicine, drugs, etc., and to make efforts to solve them (co-creation), and to continue this effort.
<Summary of Proceedings> 1.
Patient Involvement in Pharmaceutical Research and Development
- Understanding and implementation of patient involvement varies among stakeholders, with challenges specific to diseases, fields, and individual stakeholders. Patient Involvement in Pharmaceutical Research and Development
- To resolve issues and promote patient involvement, cross-stakeholder dialogue, information sharing, mutual understanding, and improved literacy To resolve issues and promote patient involvement, cross-stakeholder dialogue, information sharing, mutual understanding, and improved literacy are necessary.
- While "patient involvement" is just beginning, the aim is to move toward "public involvement" in the future.
Approaches to Information Provision
- In an era where anyone can disseminate and access information through social media, there is a need to create an environment where appropriate In an era where anyone can disseminate and access information through social media, there is a need to create an environment where appropriate information reaches healthcare professionals and patients at the right time.
- Information on stable supply, safety, and clinical trials can be life-critical for patients. It is necessary for all stakeholders, including It is necessary for all stakeholders, including government, healthcare professionals, patient organizations, and pharmaceutical companies, to collaborate in considering better ways of providing information.
JPMA will continue to work towards resolving issues related to medicines and treatments needed by patients and their families, and realizing a more
JPMA will continueto
work towards resolving issues related to medicines and treatments needed by patients and their families, and realizing a morelivable society through co-creation with the stakeholders gathered at this Meeting.
* Seven organizations and groups (in no particular order): Japan Federation of Cancer Patient Groups, Japan Intractable Diseases and Diseases Society, Representative of Self-help Group of Cancer Patient Groups, Japan Intractable Diseases and Diseases Society, Japan Intractable Diseases Society, Japan Intractable Diseases Society, and Japan Intractable Diseases Society. Representative of Self-help Group of Organic Acidemias and Fatty Acid Oxidation Disorders HIDAMARI TANPOPO," Specified NPO ASrid, Ministry of Health, Labour and Welfare, Pharmaceuticals Health, Labour and Welfare, Pharmaceuticals and Medical Devices Agency, JPMA
** Stakeholders: Patient organizations, patients and families, healthcare professionals, academia, government/authorities, pharmaceutical companies, etc.
<Reference: Event Overview
Date and Time: November 1, 2024 (Friday) 13:15-15:15
Venue: Nihonbashi Life Science Building, 10th Floor Conference Room
Facilitator: Specified NPO ASrid
Organizer: JPMA (Patient Cooperation Committee)
Discussion Themes: 1) Patient Involvement in Pharmaceutical Research and Development, 2) Approach to Providing Information
[Participants] (In alphabetical order)
Shinsuke Amano (President, Japan Federation of Cancer Patient Groups)
Yasuhiro Fujiwara (Chief Executive, Pharmaceuticals and Medical Devices Agency)
Akiko Kashiwagi (Representative of Self-help Group of Organic Acidemias and Fatty Acid Oxidation Disorders HIDAMARI TANPOPO)
Yukiko Nishimura (President and Founder, Specified NPO ASrid)
Naomi Sakurai (Director, Japan Federation of Cancer Patient Groups)
Kunio Tsuji (Managing Director, Japan Patients Association)
Hiroyuki Uchiyama (Assistant Vice-Minister for Pharmaceutical Industry Promotion and Medical Information Management, MHLW)
Hiroaki Ueno (President, Japan Pharmaceutical Manufacturers Association)
All conference participants (honorifics omitted)
Back row: Yasuhiro Fujiwara, Shinsuke Amano, Hiroyuki Uchiyama, Kunio Tsuji
Front row: Hiroaki Ueno, Akiko Kashiwagi, Naomi Sakurai, Yukiko Nishimura
Front row: Hiroaki Ueno, Akiko Kashiwagi, Naomi Sakurai, Yuki Nishimura
Public Relations Japan Pharmaceutical Manufacturers Association